Free tool
FAERS Monitor: Betapace Af
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021151 or its brand name (Betapace Af, Sotalol Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
2,600
Serious
2,156
83% of reports
Hospitalization
1,143
Death reported
260
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- atrial fibrillation186
- drug ineffective151
- electrocardiogram qt prolonged149
- hypotension125
- dyspnoea119
- dizziness116
- bradycardia112
- drug interaction99
- fatigue97
- nausea95
- fall87
- off label use73
- ventricular tachycardia73
- acute kidney injury72
- asthenia65
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 53 |
| 2005 | 32 |
| 2006 | 128 |
| 2007 | 237 |
| 2008 | 43 |
| 2009 | 128 |
| 2010 | 36 |
| 2011 | 90 |
| 2012 | 111 |
| 2013 | 63 |
| 2014 | 70 |
| 2015 | 56 |
| 2016 | 80 |
| 2017 | 98 |
| 2018 | 124 |
| 2019 | 147 |
| 2020 | 112 |
| 2021 | 95 |
| 2022 | 142 |
| 2023 | 152 |
| 2024 | 194 |
| 2025 | 254 |
| 2026 | 155 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,559 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ventricular tachycardiaSignal | 73 | 35.9 | 28.6 | 2,434 |
| electrocardiogram qt prolongedSignal | 149 | 33.6 | 28.8 | 4,676 |
| bradycardiaSignal | 112 | 17.1 | 14.3 | 1,685 |
| atrial fibrillationSignal | 186 | 15.5 | 13.5 | 2,511 |
| drug interactionSignal | 99 | 5.1 | 4.2 | 320 |
| hypotensionSignal | 125 | 5.0 | 4.3 | 405 |
| acute kidney injurySignal | 72 | 3.8 | 3.0 | 147 |
| fallSignal | 87 | 2.1 | 1.7 | 51 |
| dizziness | 116 | 1.9 | 1.6 | 48 |
| dyspnoea | 119 | 1.7 | 1.4 | 35 |
| asthenia | 65 | 1.4 | 1.1 | 7 |
| fatigue | 97 | 1.0 | 0.8 | 0 |
| nausea | 95 | 1.0 | 0.8 | 0 |
| drug ineffective | 151 | 0.9 | 0.8 | 1 |
| off label use | 73 | 0.7 | 0.5 | 12 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.